Faculty

Back to Index
Giridharan Ramsingh, MBBS, MD
Assistant Professor of Medicine
Medicine
1450 Biggy St. Health Sciences Campus Los Angeles
+1 323 442 8071

Overview

Dr. Ramsingh's laboratory research interests include genetic changes underlying the development of leukemia in patients previously treated with chemotherapy. He is particularly focused on understanding the mechanism of aging in Hematopoietic stem and progenitor cells and its contribution to leukemogensis.

Dr. Ramsingh earned his medical degree from Christian Medical College, and then stayed on to perform his internship and residency. He then completed two fellowships, one in hematology/oncology, and the other in stem cell biology at Washington University School of Medicine.

Awards

Tower Cancer Foundation: Career Development Award, 2014-2015

STOP Cancer: Career Development Award, 2013-2016

Washington University: Translational Oncology Pilot Grant Award, 2012

Americaf Society for Blgod and Marrow Transplantation: Travel Award, 2010

American Society for Blood and Marrow Transplantation: Travel Award, 2010

American Association of Cancer Research: Translational Cancer Medicine Travel Award, 2010

American Society of Clinical Oncology: Young Investigator Award, 2009-2010

American Society of Hematology: Travel Award, 2009

Christian Medical College: Best Outgoing Medical Student, 1999

National Council for Education Research and Training: Scholarship, 1993-2002

Publications

Suppression of Transposable Elements in Leukemic Stem Cells. Sci Rep. 2017 Aug 01; 7(1):7029. View in: PubMed

Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1072-1077. View in: PubMed

. View in: PubMed

Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017 Mar 17. View in: PubMed

Arkas: Rapid reproducible RNAseq analysis. F1000Res. 2017; 6:586. View in: PubMed

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol. 2014 Mar; 99(3):272-8. View in: PubMed

Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood. 2013 Oct 10; 122(15):e44-51. View in: PubMed

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia. 2013 Mar; 27(3):725-8. View in: PubMed

Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010 Dec 09; 116(24):5316-26. View in: PubMed

Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010 Dec 9; 116(24):5316-26. View in: PubMed

Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res. 2010 Nov; 20(11):1590-604. View in: PubMed

Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009 Dec 15; 115(24):5734-9. View in: PubMed

Prognostic factors influencing survival in solitary plasmacytoma. Br J Haematol. 2009 May; 145(4):540-2. View in: PubMed

Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Aug; 49(8):1560-6. View in: PubMed

Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer. 2008 May 15; 112(10):2233-40. View in: PubMed

Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol. 2007 Feb; 31(2):233-9. View in: PubMed

Powered bySC CTSI